Clinical-stage biopharmaceutical company Spring Bank Pharmaceutical has appointed a CMO.
Nezam Afdhal, MD, will serve as the company's CMO. Dr. Afdhal has been with the company as a consultant since 2011 and non-executive CMO since this year.
"I am delighted that Dr. Afdhal has joined the Spring Bank Management Team to lead the next stage of our company's clinical development strategy," said Martin Driscoll, president and CEO of Spring Bank. "Since 2011, our company has worked extensively with Dr. Afdhal in the area of liver disease and antiviral drug development."
Spring Bank focuses on developing novel therapeutics for the treatment of viral infections.
Dr. Afdhal will continue to practice as a senior physician at the Beth Israel Deaconess Medical Center's Liver Center in Boston.